BioSpace News Archive

The Alzheimer’s Clinical Trials Consortium and Eisai Co., Ltd. announced that the investigational oral BACE inhibitor elenbecestat and the investigational anti-amyloid beta protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer’s disease, have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention and secondary prevention of AD.

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV.

AngioDynamics, Inc. announced enrollment of the first patient in its NanoKnife® Irreversible Electroporation “Data IRE Cancer Treatment” clinical study.

This year’s annual meeting is held in New Orleans and is a gathering of the most prestigious society of rhinoplasty surgeons in the world.

The systems are expected to be installed by October 2019.

FLX193 Presents Potentially Attractive Alternative to Treatment with Injectable Biologics or Topical Corticosteroids

Previous analysis demonstrated robust and statistically significant clinical benefits of the drug in moderate to severe knee OA.

Bayer will present research from its expanding oncology portfolio at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago.

New leader reflects the company’s commitment to continued expansion of solutions for physicians and medical practices

Mdcl today announced it has joined the NVIDIA Inception program, which is designed to nurture startups that are revolutionizing industries with advancements in AI and data sciences.